+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Banzel"

From
From
Epilepsy Forecast and Market Analysis to 2035 - Product Thumbnail Image

Epilepsy Forecast and Market Analysis to 2035

  • Drug Pipelines
  • July 2019
  • 345 Pages
  • Global
From
Antiepileptic Drugs Market - Forecast (2022 - 2027) - Product Thumbnail Image

Antiepileptic Drugs Market - Forecast (2022 - 2027)

  • Report
  • January 2022
  • 137 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Banzel (rufinamide) is a medication used to treat seizures associated with Lennox-Gastaut Syndrome (LGS). It is a member of the class of drugs known as anticonvulsants, which work by decreasing abnormal electrical activity in the brain. Banzel is approved by the U.S. Food and Drug Administration (FDA) for use in adults and children four years of age and older. It is available as a tablet and an oral suspension. Banzel is part of the Central Nervous System (CNS) drug market, which includes medications used to treat a variety of neurological conditions, such as epilepsy, Parkinson's disease, and Alzheimer's disease. CNS drugs are typically used to reduce symptoms and improve quality of life. Some companies in the Banzel market include Eisai Co., Ltd., Sunovion Pharmaceuticals Inc., and UCB Pharma. Show Less Read more